bluuebunny/crossref_metadata_2025_split huggingface dataset:
Multifamily therapy for adolescent eating disorders: a study of the change in eating disorder symptoms from start of treatment to follow-up
Authors: Funderud Ingrid , Halvorsen Inger , Kvakland Anne-Lise , Nilsen Jan-Vegard , Skjønhaug Jeanette , Stedal Kristin , Rø Øyvind 
Published: June 2023

Abstract
Background
This study aimed to evaluate multifamily therapy (MFT) for adolescents with eating disorders (EDs) in a clinical setting, by presenting the outcome of families participating in this treatment at a specialist ED service. MFT was an adjunct to treatment at local mental health services. In particular, the study aimed to present the change in eating disorder symptoms and psychological distress from before to after treatment and at a 6 months follow-up.

Methods
Participants were 207 adolescents receiving outpatient MFT (10 or 5 months) at Oslo University Hospital in Norway between 2009 and 2022. Adolescents had heterogeneous ED presentations, with a preponderance of anorexia nervosa (AN) and atypical AN. All participants completed pre- and post-treatment questionnaires [The eating disorder examination questionnaire (EDE-Q) and the strengths and difficulties questionnaire (SDQ)]. 142 adolescents additionally completed the same questionnaires at 6 months follow-up. Weight and height were measured at all time points.

Results
Linear mixed model analyses showed that from start of treatment to follow-up, there was a significant increase in BMI percentile (p < 0.001) and a significant decrease in EDE-Q global score (p < 0.001) and SDQ total score (p < 0.001).

Conclusions
The study shows that adolescents with an eating disorder who received adjunct outpatient MFT in a real world clinical setting, experienced reductions in ED symptoms comparable to that found in a randomized controlled trial.
Trial registration: The data used in this study was collected as part of routine clinical procedures for quality assurance and trial registration is therefore not required.
Antifungal and consolidation properties of linen textiles treated with silver nanoparticles loaded on hydroxypropyl cellulose polymer
Authors: Abo-Elmaaref Mahmoud , Marouf Mohamed , Mohamed W. S. , Abdel Wahab Walaa A. 
Published: June 2023

Abstract
Microorganisms are considered one of the most dangerous deterioration factors to cellulosic textiles, especially textiles made of linen fibers. Many of the traditional methods of resistance to microorganisms that infect textiles were used in the past, but they were of low effectiveness and high toxicity for those who applied these methods. The study used silver nanoparticles (AgNPs) prepared by the chemical reduction of silver nitrate (AgNO3) in the presence of a polyvinylpyrrolidone (PVP) polymer as a stabilizing agent in inhibiting fungal strains Aspergillus flavus, Trichoderma sp. and Penicillium duclauxii that were isolated from the ancient linen piece No. 1345 preserved in the Sohag National Museum. The properties of the silver nanoparticles prepared and loaded on hydroxypropyl cellulose (Klucel G 1%) polymer were studied by many of examination and analysis methods such as TEM, XRD and FTIR. Evaluating the effectiveness of AgNPs/Klucel G by using well-cut diffusion technique revealed that the best concentration of AgNPs in inhibiting fungal strains is 3%. The results of treating raw and dyed linen textiles using AgNPs/Klucel G also indicated an improvement in the mechanical and chemical properties of the treated textiles. One of the most important results of the study is obtaining raw and dyed linen textiles with resistant properties to isolated fungal strains up to 3 months of treatment.

Graphical Abstract
Operational strategies to alleviate thermal impacts of the large-scale borehole heat exchanger array in Beijing Daxing Airport
Authors: Ren Yaqian , Kong Yanlong , Huang Yonghui , Bie Shu , Pang Zhonghe , He Jichao , Yi Wei , He Bin , Wang Jiyang 
Published: June 2023

AbstractLarge-scale ground source heat pump (GSHP) systems are increasingly used for space heating and cooling. In comparison with smaller ones, large GSHP systems are often coupled with much more borehole heat exchangers (BHEs). Because of the intense thermal interactions between BHEs, they are more susceptible to significant ground temperature changes. Meanwhile, they possess the advantage that their operational strategies can be applied with a high degree of freedom, which presents chances to alleviate intense thermal interactions. In this study, we used a new performance indicator to access the effectiveness of GSHP operational strategies on alleviating thermal anomalies. The Daxing Airport GSHP system, contains 10,497 BHEs and is the largest in the world; therefore, it was selected as the test case for performance enhancement through operational strategies. We established a 2D model to predict ground temperature changes during the 50-year operation of the BHEs. First, it was revealed that the most severe thermal anomalies in the study area mainly occurred both within and between the BHE arrays, which should be mitigated. To alleviate the thermal anomalies caused by the thermal interactions of BHEs, operational strategies were applied by adjusting the cooling/heating starting sequence, setting time-dependent thermal loads, and reallocating thermal loads according to the position of the BHEs. Our study demonstrates that only the operation strategy that adjusts the cooling/heating starting sequence is beneficial for different BHE layouts, while the operational strategy that reallocates the thermal loads depending on BHEs position may be only effective for specific BHE layouts. In addition, our new performance indicator can be used to evaluate the effectiveness of the operational strategies and determine the spacing of adjacent BHE arrays. Therefore, it benefits the operation management of BHE array and design of BHE layout, and further guarantees the sustainable operation of the GSHP system.
Successful treatment of postoperative nonobstructive recurrent cholangitis by tract conversion surgery after total pancreatectomy: a case report
Authors: Odaira Masanori , Toriumi Fumiki , Hoshino Shota , Iwama Nozomi , Ito Yasuhiro , Endo Takashi , Harada Hirohisa 
Published: June 2023

Abstract
Background
Postoperative cholangitis is a complication of biliary reconstruction during hepatobiliary pancreatic surgery. Most cases are associated with anastomotic stenosis, but there are also cases of cholangitis without stenosis, and treatment can be difficult, especially in patients with recurrent symptoms. In this report, we describe a case of repeated nonobstructive cholangitis in a patient after total pancreatectomy, in which a good outcome was obtained after performing tract conversion surgery.

Case presentation
The patient was a 75-year-old man. He underwent total pancreatectomy for stage IIA cancer of the pancreatic body, hepaticojejunostomy via the posterior colonic route, gastrojejunostomy and Braun anastomosis via the anterior colonic route using the Billroth II method. The patient had a good postoperative course and was receiving adjuvant chemotherapy on an outpatient basis, but he developed his first episode of cholangitis 4 months after surgery. Although conservative treatment with antimicrobial agents was successful, the patient continued to have recurrent biliary cholangitis and was repeatedly admitted and discharged from the hospital. Since stenosis at the anastomosis was suspected, endoscopic observation of the anastomosis was performed using small bowel endoscopy for close examination, but no apparent stenosis was observed. Small bowel imaging indicated a possible influx of contrast medium into the bile duct, and reflux due to food residue was suspected as the cause of cholangitis. Since conservative treatment alone did not suppress the flare-up of symptoms, the decision was made to perform tract conversion surgery for curative purposes. The afferent loop was cut midstream, and jejunojejunostomy was performed downstream. The postoperative course was good, and the patient was discharged on the 10th day after surgery. He is currently an outpatient and has been free of cholangitis symptoms for 4 years without cancer recurrence.

Conclusions
Although the diagnosis of nonobstructive retrograde cholangitis can be difficult, surgical treatment should be considered in patients with recurrent symptoms and refractory treatment.
Chemo-preventive effects and antitumorigenic mechanisms of beer and nonalcoholic beer toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) - induced lung tumorigenesis in A/J mice
Authors: Takata Jun , Kiura Katsuyuki , Nakasuka Takamasa , Hirabae Atsuko , Arimoto-Kobayashi Sakae 
Published: June 2023

AbstractWe investigated the chemopreventive effects of beer, nonalcoholic beers (NABs), and beer-components (glycine betaine (GB)) on NNK-induced lung tumorigenesis in A/J mice, and the possible mechanisms underlying the antitumorigenic effects of beer, NABs, and beer-components. Beer, NABs, and GB reduced NNK-induced lung tumorigenesis. We investigated the antimutagenicity of beer, NABs and beer-components (GB and pseudouridine (PU)) toward the mutagenicity of 1-methyl-3-nitro-1-nitrosoguanidine (MNNG) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Beer, NABs, and beer components were antimutagenic toward MNNG and NNK in the Ames test using S. typhimurium TA1535. In contrast, MNNG and NNK mutagenicity detected in S. typhimurium YG7108, a strain lacking O6-methylguanine DNA methyltransferases (ogtST and adaST) did not decrease in the presence of beer, NABs, or beer components, suggesting that they may mediate its antimutagenic effect by enhancing DNA damage repair. Phosphorylation of Akt and STAT3, with or without epidermal growth factor stimulation, in lung epithelial-like A549 cells were significantly decreased following beer, NABs, GB and PU. They targeted both the initiation and growth/progression steps of carcinogenesis, specifically via antimutagenesis, stimulation of alkyl DNA-adduct repair, and suppression of Akt- and STAT3- mediated growth signaling. GB and PU may contribute, in part, to the biological effects of beer and NABs via the suppression of Akt and STAT3 phosphorylation.
Factors affecting in vitro tuberization of potato
Authors: Mohamed Adel El-Sawy , Girgis Nancy Danial 
Published: June 2023

Abstract
Background
Potato (Solanum tuberosum L.) is one of the most economically important annual vegetable crops. Microtubers can be produced, stored around year and directly transported to market without transferring to fresh media and without acclimatization. Thus reducing the field cycle to obtain sufficient number of seed potatoes and a high level of healthy materials. The aim of this study was to investigate effects of different combinations and concentrations of growth regulators i.e., kinetin (2.5 mg/l) and coumarin (20, 40 and 60 mg/l) alone or in addition to varied concentrations of sucrose (30, 60 and 90 g/l) on in vitro tuberization of potato (Solanum tuberosum) cv. Diamount.

Results
The plantlets were propagated using single-node cuttings cultured on Murashige and Skoog medium containing 0.04 mg/l kinetin and 1.0 mg/l IAA. Shoots (6–7 nodes) from the previous step were cultured into medium supplemented with a factorial combination of sucrose concentrations (30, 60 and 90 g/l), coumarin concentrations (0, 20, 40, and 60 mg/l) and two concentrations of kinetin (0 and 2.5 mg/l). Our results showed that kinetin – induced medium have slightly effect to improve tuberization in vitro. But when kinetin was combined with sucrose, this effect was better when raised sucrose concentration from 30 or 60 to 90 g/l. The highest percentage of tuberization after 8 weeks, highest number of microtuber were obtained with high concentration of sucrose (90 g/l) together with dark condition, at 18–20 °C. Also, the highest concentration of sucrose significantly increased the fresh weight of microtuber. In case of coumarin, results revealed that it has important effect on tuber initiation especially with concentrations 20 mg/l and 40 mg/l; otherwise, the initiation period was minimized after adding kinetin. So, the plantlets must be continuously incubated in coumarin –induce medium plus kinetin for 8 weeks to affect the tuberization response. Also, all the other characters of tuberization process on coumarin-inducing medium could be improved by increasing sucrose concentration to 9 g/l.

Conclusions
Generally, results pointed out that the treatment which consists of kinetin (2.5 mg/l) plus 90 g/l sucrose and 20 mg/l coumarin has the best characteristics of in vitro micro-tuberization.
Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients
Authors: Saleeb Mina Fayez , Sabry Sabry Magdy , Mahmoud Mohammad Salah , Nassif Mena Maher 
Published: June 2023

Abstract
Background
Mucormycosis is a serious life-threatening fungal infection that recently made severe sudden and devastating surge during the second wave of the COVID-19 epidemic with a mortality rate of up to 50%.
Although the causality link between COVID-19 and rhino-orbito-cerebral mucormycosis (ROCM) remains unclear, many factors including poor diabetes control, high doses of steroids, viral-induced lymphopenia, and cytokine storm have been attributed to ROCM in patients with COVID-19.
Orienting to risk factors and early recognition of this potentially fatal opportunistic infection is the key to optimal management and improved outcomes. In these contexts, we conducted a prospective study for 33 patients admitted to our tertiary hospital to determine the risk factors for ROCM in patients with COVID-19 and the cumulative mortality rates.

Results
This study found a statistically significant relation between the fate of death in COVID-MUCOR patients who had presented fever, ophthalmoplegia, facial skin necrosis, and visual loss with those who received dose of steroid to control their respiratory symptoms P < 0.001.
Death from COVID-MUCOR was statistically significant related to the prolonged interval from the onset of the symptoms to start of treatment and intervention. Also, it was found that there was a significant decrease in duration between COVID-19 infection and the start of mucormycosis (days) with incidence of DKA on admission. Nineteen (57.6%) of the patients had uncontrolled diabetes mellitus (hemoglobin A1C (HbA1c) of > 7.0%).

Conclusion
Mucormycosis epidemic was precipitated by a unique confluence of risk factors: diabetes mellitus, widespread use of steroids, and perhaps SARS-CoV-2 infection itself. Restricting steroid use in patients with severe COVID-19 requiring oxygen therapy, and screening for and optimally controlling hyperglycemia, can prevent COVID-MUCOR in a large majority.
SARS-CoV-2 and risk of psychiatric hospital admission and use of psychopharmaceuticals: A nationwide registry study of 4,585,083 adult Danish citizens
Authors: Rømer Valdemar , Sivapalan Pradeesh , Eklöf Josefin , Nielsen Susanne D. , Harboe Zitta B. , Biering-Sørensen Tor , Itenov Theis , Jensen Jens-Ulrik S. 
Published: June 2023

Abstract

Background
Current evidence on the risk of admission- or medication-requiring psychiatric sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is limited to selected populations, short durations, and loss to follow-up. This study examined if SARS-CoV-2 infection was associated with increased long-term risk of psychiatric admissions and de novo prescription of psychoactive medication in the general population of Denmark.

Methods
Adults (≥18 years) were assigned to either the control or SARS-CoV-2 group based on polymerase chain reaction (PCR) tests between 1 January 2020 and 27 November 2021. Infected subjects were matched 1:5 to control subjects by propensity score. Incidence rate ratios (IRRs) were calculated. Adjusted Cox regression was applied to the unmatched population with SARS-CoV-2 infection as a time-dependent covariate. Follow-up time was 12 months or until the end of the study.

Results
A total of 4,585,083 adults were included in the study. Approximately 342,084 had a PCR-confirmed SARS-CoV-2 infection and were matched 1:5 with 1,697,680 controls. The IRR for psychiatric admission was 0.79 in the matched population (95% confidence interval [CI]: 0.73–0.85, p < 0.001). In the unmatched population, the adjusted hazard ratios (aHR) for psychiatric admission were either below 1.00 or with a 95% CI lower limit of 1.01. SARS-CoV-2 infection was associated with an increased risk of de novo prescription of psychoactive medication in both the matched (IRR 1.06, 95% CI: 1.02–1.11, p < 0.01) and unmatched population (HR 1.31, 95% CI: 1.28–1.34, p < 0.001).

Conclusions
We found a signal of increased use of psychoactive medication, specifically benzodiazepines, among SARS-CoV-2-positive persons, but the risk of psychiatric admissions did not increase.
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Authors: Meric-Bernstam Funda , Makker Vicky , Oaknin Ana , Oh Do-Youn , Banerjee Susana N. , Gonzalez Martin Antonio , Jung Kyung Hae , Lugowska Iwona A. , Manso Luis , Manzano Aránzazu , Melichar Bohuslav , Siena Salvatore , Stroyakovskiy Daniil , Anoka Chiedozie , Ma Yan , Puvvada Soham D. , Lee Jung-Yun 
Published: June 2023

LBA3000 Background: T-DXd is an antibody drug conjugate targeting HER2 and is approved in HER2-expressing breast (BC) and gastric (GC) cancers. HER2 expression is prevalent in other solid tumors. The efficacy of current treatments (Tx) in these populations, including studies with HER2-directed Tx, is modest, revealing a significant unmet medical need. Clinically meaningful activity of T-DXd was seen in HER2-expressing tumors in a phase 1 study (NCT02564900). Methods: DP-02 (NCT04482309) is an open-label phase 2 study of T-DXd 5.4 mg/kg q3w in pts with HER2-expressing (immunohistochemistry [IHC] 3+ or IHC 2+ by local or central testing) locally advanced or metastatic disease that progressed after ≥1 systemic Tx or that has no Tx options. Cohorts with biliary tract (BTC), bladder (URO), cervical (CC), endometrial (EC), ovarian (OC), pancreatic (PC), or other tumors (excluding BC, GC, colorectal cancer, and non-small cell lung cancer) were enrolled. Efficacy and safety were analyzed in all pts who received ≥1 dose of T-DXd. The primary endpoint was investigator-assessed confirmed objective response rate (ORR). Secondary endpoints included duration of response (DOR), disease control rate, progression-free and overall survival, and safety. Results: At data cutoff (16 Nov 2022; median follow-up, 9.7 mo), 267 pts had been treated (median, 2 prior lines of Tx [range, 0-13]); 75 pts were IHC 3+ and 125 were IHC 2+ by central testing. In all 267 pts, the ORR was 37.1% and median DOR (mDOR) was 11.8 mo; in pts with IHC 3+ expression, the ORR was 61.3% and mDOR was 22.1 mo. ORR per cohort is shown in all pts and those with centrally confirmed HER2 IHC 3+ or IHC 2+ expression. Grade (G) ≥3 adverse events (AEs) occurred in 58.4% of pts; 11.6% discontinued Tx due to AEs. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 18 pts (6.7% [G1, n=6; G2, n=11; G5, n=1]). Conclusions: This is the first tumor-agnostic global study of T-DXd in a broad range of HER2-expressing solid tumors. T-DXd showed encouraging ORR, particularly in pts with IHC 3+ expression, durable clinical benefit, and a manageable safety profile in this heavily pretreated population. These interim results show T-DXd to be a potential new Tx option for pts with HER2-expressing solid tumors. Clinical trial information: NCT04482309 . [Table: see text]
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
Authors: Loriot Yohann , Matsubara Nobuaki , Park Se Hoon , Huddart Robert A , Burgess Earle F , Houede Nadine , Banek Severine , Laguerre Brigitte , Guadalupi Valentina , Ku Ja Hyeon , Triantos Spyros , Akapame Sydney , Deprince Kris , Mukhopadhyay Sutapa , Siefker-Radtke Arlene O. 
Published: June 2023

LBA4619 Background: FGFRalt are observed in ~20% of pts with mUC. Erda is an oral selective pan-FGFR tyrosine kinase inhibitor granted accelerated approval to treat locally advanced or mUC in adults with susceptible FGFR3/2alt who have progressed after platinum-containing chemo. THOR (NCT03390504), a randomized phase 3 study, assessed whether erda provided a survival advantage vs investigator’s choice of chemo in pts with mUC who progressed after 1 or 2 prior treatments, including an anti-PD-(L)1 agent. Methods: Pts (≥18 y) with unresectable advanced/mUC and select FGFR3/2alt (mutations/fusions), ECOG performance status 0-2, adequate organ function, progression on/after prior systemic therapy (tx) that included an anti-PD-(L)1 agent, and ≤2 prior lines of tx were randomized 1:1 to receive erda (8 mg with pharmacodynamically guided uptitration to 9 mg on day 14) QD or investigator’s choice of chemo (docetaxel or vinflunine) Q3W until disease progression or intolerable toxicity. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. Results: 266 pts were randomized: 136 pts assigned to erda, 130 to chemo. In all pts, median age was 67 y; 30% had 1 prior line of tx, 70% had 2 prior lines; 74% had visceral metastases; 90% were PD-L1 low (CPS <10). Median follow-up was 15.9 mo. The primary endpoint of the study was met, with erda significantly increasing OS and reducing the risk of death by 36%; median OS was 1 y (Table). These data met predefined stopping criteria for superiority. Erda also significantly improved median PFS (5.6 vs 2.7 mo) and ORR (46% vs 12%) vs chemo. No new safety signals were seen. Serious treatment-related adverse events (TRAEs) were observed in 13% and 24% of pts with erda and chemo, respectively, and grade (Gr) 3/4 TRAEs were observed in 46% and 46% of pts with erda and chemo, respectively. TRAEs leading to death were reported in 1 and 6 pts with erda and chemo, respectively. More TRAEs leading to dose reduction were observed with erda (66%) vs chemo (21%); 8% and 13% of pts had TRAEs leading to discontinuation of erda and chemo, respectively. Central serous retinopathy occurred in 23 pts (17%) with erda (Gr 1-2, 20 pts). Conclusions: In pts with FGFRalt advanced/mUC after prior treatment with PD-(L)1, erda significantly improved OS, PFS, and ORR vs investigator’s choice of chemo. Erda toxicity was consistent with the known safety profile. These results support the role of erda to treat pts with FGFRalt mUC after PD-(L)1 tx. Clinical trial information: NCT03390504 . [Table: see text]